Jefferies Global Healthcare Conference
Logotype for Gilead Sciences Inc

Gilead Sciences (GILD) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Gilead Sciences Inc

Jefferies Global Healthcare Conference summary

17 Nov, 2026

Business outlook

  • Q3 delivered the strongest growth in more than a decade, with contributions across HIV, oncology and inflammation; management expects strong top- and bottom-line growth ahead.

  • HIV growth, oncology expansion and inflammation investment are diversifying the portfolio; BIKTARVY’s 2036 patent expiry is identified as the only major patent cliff.

Inflammation strategy

  • Oral alpha-4-beta-7 phase II data were described as potentially matching IV or injectable efficacy with good tolerability; development will pursue monotherapy and combinations in UC and IBD.

  • Tolerability may support use in moderate and milder disease; an in-licensed potent IL-23 peptide has potential for once-monthly dosing and possible oral combinations or co-formulation.

  • Inflammation is positioned as a 2030 growth opportunity; gamgertamig, a BCMAxCD3 B-cell depleter, could be the first potential launch, potentially in the early 2030s.

Oncology and Tubulis

  • Tubulis’ lead NaPi2b ADC targets ovarian cancer, with potential in endometrial and lung cancers; 5T4 and additional payloads are also in development.

  • Management highlighted the tight linker’s potential to support combinations with chemotherapy or other agents, across ovarian cancer and other tumor types.

  • Management expressed confidence in the ovarian cancer dose and expects to share more data in 2027; external combination partnerships remain an option.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Gilead Sciences